Precigen (PGEN) Stock Analysis & Winston Score
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL
Winston Score: 27/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (10/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Weak (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $4.95
Market Cap: $1.5B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
